{"id":"NCT00320424","sponsor":"GlaxoSmithKline","briefTitle":"Hip Fracture Study of GSK576428 (Fondaparinux Sodium)","officialTitle":"Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism After Hip Fracture Surgery","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-02-16","primaryCompletion":"2006-10-26","completion":"2006-10-26","firstPosted":"2006-05-03","resultsPosted":"2017-10-11","lastUpdate":"2018-09-04"},"enrollment":48,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Thromboembolism"],"interventions":[{"type":"DRUG","name":"Fondaparinux","otherNames":[]}],"arms":[],"summary":"This study is requested by PMDA to confirm the efficacy and the safety for HFS.","primaryOutcome":{"measure":"Rate of Major Bleeding During Treatment Period","timeFrame":"From the first study drug injection up to Day 17","effectByArm":[{"arm":"Fondaparinux Sodium 2.5 mg s.c.","deltaMin":21.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":1,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":48},"commonTop":["Constipation","Insomnia","Oedema peripheral","Excoriation","Dermatitis contact"]}}